PURPOSE: Next-generation sequencing (NGS) is a crucial component of evaluation of
patients with newly diagnosed metastatic non–small-cell lung cancer (NSCLC) to determine …

9079 Background: National guidelines recommend biomarker testing in mNSCLC, and
targeted therapy is associated with improved outcomes. The aim of this study was to …

Background Data are scarce regarding real-world health care resource use (HCRU) for non-
small cell lung cancer (NSCLC). An understanding of current clinical practices and HCRU is …

Importance Valuable evidence regarding clinical characteristics, treatments, and outcomes
for non–small cell lung cancer (NSCLC) is limited to individual hospital databases or …

PURPOSE Large, generalizable real-world data can enhance traditional clinical trial results.
The current study evaluates reliability, clinical relevance, and large-scale feasibility for a …

Background This study aimed to describe treatment patterns and overall survival (OS) in
patients with advanced non–small cell lung cancer (aNSCLC) in three countries between …

Importance Updated estimates of non–small cell lung cancer (NSCLC) in the US are
needed. Objective To calculate the most recent epidemiologic estimates of NSCLC in the …

Introduction Multiple therapeutic options now exist for metastatic non–small-cell lung cancer
(mNSCLC). In this study we evaluated treatment patterns and outcomes in mNSCLC …

PURPOSE Real-world lung cancer data in administrative claims databases often lack
staging information and specific diagnostic codes for lung cancer histology subtypes. This …

Importance Despite recent breakthroughs in therapy, advanced lung cancer still poses a
therapeutic challenge. The survival profile of patients with metastatic lung cancer remains …